StockData
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. (ANTX) stock

ANTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$4.55+0.11 (+2.48%)

Close on Nov 13, 2026Market cap $171.70MP/E –Yield –

AN2 Therapeutics cash

Cash and short-term investments held at the end of each period.

AN2 Therapeutics's cash was $64.40M at Sep 30, 2026. For fiscal 2025 it was $58.00M, down 30.6% from the year before. The highest annual figure on record is $107.30M in fiscal 2023.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$58.00M-30.6%
FY2024Dec 31, 2024$83.62M-22.1%
FY2023Dec 31, 2023$107.30M+8.1%
FY2022Dec 31, 2022$99.30M+69.6%
FY2021Dec 31, 2021$58.56M+1338.7%
FY2020Dec 31, 2020$4.07M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$64.40M+4.0%
Q2 FY2026Jun 30, 2026$78.39M+24.6%
Q1 FY2026Mar 31, 2026$85.29M+27.2%
Q4 FY2025Dec 31, 2025$58.00M-30.6%
Q3 FY2025Sep 30, 2025$61.92M-33.7%
Q2 FY2025Jun 30, 2025$62.92M-39.8%
Q1 FY2025Mar 31, 2025$67.06M-41.3%
Q4 FY2024Dec 31, 2024$83.62M-22.1%
Q3 FY2024Sep 30, 2024$93.43M-24.5%
Q2 FY2024Jun 30, 2024$104.54M+9.7%
Q1 FY2024Mar 31, 2024$114.21M+29.1%
Q4 FY2023Dec 31, 2023$107.30M+8.1%
Q3 FY2023Sep 30, 2023$123.82M+18.6%
Q2 FY2023Jun 30, 2023$95.30M-16.0%
Q1 FY2023Mar 31, 2023$88.50M-25.3%
Q4 FY2022Dec 31, 2022$99.30M+69.6%
Q3 FY2022Sep 30, 2022$104.40M+560.2%
Q2 FY2022Jun 30, 2022$113.40M+308.9%
Q1 FY2022Mar 31, 2022$118.40M+43.9%
Q4 FY2021Dec 31, 2021$58.56M+1338.7%
Q3 FY2021Sep 30, 2021$15.81M–
Q2 FY2021Jun 30, 2021$27.73M–
Q1 FY2021Mar 31, 2021$82.27M–
Q4 FY2020Dec 31, 2020$4.07M–

More AN2 Therapeutics figures

See a number that looks wrong?